BPC-157 Side Effects: Short- and Long-Term Safety Profile
BPC-157 is widely marketed for injury recovery, gut healing, and performance, but it is not FDA-approved for any of these uses. Human safety data is severely limited, and the FDA has identified potential significant safety concerns.
BPC-157 is not FDA-approved and has no controlled human safety data. The FDA has flagged it for potential immunogenicity, impurity, and characterisation risks. Side effects are poorly characterised, absence of reports is not evidence of safety.
Key Takeaways
- BPC-157 is not FDA-approved for injury recovery, gut healing, pain, bodybuilding, or any wellness use.
- The FDA has identified potential immunogenicity risks, impurity and API characterisation concerns, and states it has insufficient safety information.
- Human safety data is severely limited, animal study findings cannot establish human safety or dosing.
- Drug interactions are poorly characterised, compatibility with prescription medicines is largely speculative.
- Anyone using BPC-157 should disclose it to all treating clinicians, especially before surgery, pregnancy, cancer treatment, or immune disease care.
- Check BPC-157 against your full medication list using the Allmeds drug checker.
What is BPC-157, and what is it used for?
| Property | Detail |
|---|---|
| Full name | Body Protection Compound-157; pentadecapeptide BPC 157 |
| Type | Synthetic peptide, 15 amino acid sequence |
| FDA approval status | Not approved for any marketed use in the USA |
| TGA status (Australia) | Not approved; not listed on the ARTG for promoted uses |
| Promoted uses | Injury recovery, tendon/ligament healing, gut health, anti-inflammation, bodybuilding, none are FDA-approved |
| Evidence base | Primarily animal/preclinical; human evidence is limited and methodologically weak |
| Compounding status | FDA category: substances with potential significant safety risks |
| Anti-doping status | Prohibited substance in sport (WADA/ASADA) |
What side effects has BPC-157 been linked to?
Because BPC-157 lacks controlled human clinical trials for common marketed uses, side effects are not well characterised. The absence of reported side effects in marketing materials does not mean BPC-157 is safe, it means adequate safety studies have not been done.
Possible Side Effects (Based on Mechanism and Case Reports)
| Side Effect Domain | What May Occur | Why It Matters |
|---|---|---|
| Injection-site reactions | Pain, redness, swelling, bruising, itching, nodule formation | Common across any injected peptide; may signal contamination or irritation |
| Infection | Warmth, pus, fever, cellulitis, abscess | Non-sterile injection technique or contaminated product can cause serious infection |
| Immune / allergic reactions | Rash, hives, swelling, difficulty breathing, anaphylaxis | Peptides and impurities can trigger immune reactions, FDA notes immunogenicity risk |
| Angiogenesis effects | Theoretical concern around stimulation of unwanted tissue growth | Animal data suggests pro-angiogenic activity; long-term human impact is unknown |
| Gastrointestinal symptoms | Nausea, stomach discomfort (particularly oral route) | Reported anecdotally; no controlled incidence data available |
| Long-term effects | Entirely unknown, no long-term human studies exist | Absence of long-term data is itself a significant safety gap |
| Impurity-related effects | Effects of unlisted compounds in gray-market products | Compounded or research-grade BPC-157 may not meet pharmaceutical quality standards |
Taking BPC-157 alongside other medications?
Check BPC-157 against your full medication list instantly. Allmeds scans the widest drug interaction database in minutes.
What drugs does BPC-157 interact with?
BPC-157 drug interactions are poorly characterised. This is a critical limitation: most claims about compatibility with prescription medicines are speculative because BPC-157 has never undergone the clinical interaction testing required for approved medicines.
High-Risk Combinations, Clinician Review Required
| Drug / Drug Class | Concern | Recommendation |
|---|---|---|
| Anticoagulants (warfarin, heparin, apixaban) | Uncertain bleeding and perioperative risk; no interaction studies exist | Avoid combination without clinician review |
| Immunosuppressants (tacrolimus, cyclosporin) | Immune interactions with an incompletely characterised peptide are unpredictable | Disclose to transplant or specialist team before use |
| Cancer therapies / biologics | Pro-angiogenic and immune effects could theoretically interfere with oncology treatment | Do not use without explicit oncology approval |
| Diabetes medicines (insulin, metformin, GLP-1s) | Theoretical glucose regulation effects via GH/IGF-1-adjacent pathways | Monitor blood glucose; disclose use to endocrinologist |
| NSAIDs and anti-inflammatory drugs | Overlapping anti-inflammatory mechanisms; combined effect unknown | Inform prescribing clinician |
| Perioperative medications | Unknown interactions with anaesthetic agents, muscle relaxants, analgesics | Disclose BPC-157 use to surgical team before any procedure |
Is it safe to drink alcohol while using BPC-157?
There is no reliable clinical evidence defining a BPC-157–alcohol interaction. Because BPC-157 itself lacks robust human safety data, the absence of interaction studies should be treated as unknown risk, not proof of safety.
Alcohol may independently worsen inflammation, impair wound healing, increase bleeding risk, affect liver function, and impair judgment around sterile injection technique, all of which are relevant to anyone using injected peptides.
Common Questions About BPC-157 Side Effects
No. BPC-157 is not FDA-approved for injury recovery, gut healing, bodybuilding, or any wellness use. The FDA has listed it as a substance with potential significant safety risks for compounding.
No. Human safety data are limited, and the absence of reported side effects in marketing materials reflects a lack of adequate clinical surveillance, not a proven safety profile.
Safety has not been established for either route. Route-specific human safety data are limited, and the FDA’s concerns apply across administration routes.
The four main concerns are: unknown long-term safety, immune reactions (immunogenicity), impurities in non-pharmaceutical-grade products, and risks from non-sterile injection practices.
Yes, always. Clinicians need to know about all injected or compounded substances, particularly before surgery, pregnancy, cancer treatment, or any immune disease care. Disclosure is essential for safe clinical decision-making.
References
- U.S. Food & Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks. fda.gov.
- Therapeutic Goods Administration (Australia). Australian Register of Therapeutic Goods (ARTG), BPC-157 lookup. tga.gov.au.
- World Anti-Doping Agency. WADA Prohibited List, S0 (non-approved substances). wada-ama.org.
- Seiwerth S. et al. BPC 157 and standard angiogenic growth factors. Gastrointestinal tract healing, lessons from tendon, ligament, muscle and bone healing. Curr Pharm Des. 2018;24(18):1972–1989.
- Sikiric P. et al. Brain-gut axis and pentadecapeptide BPC 157. Curr Neuropharmacol. 2016;14(8):857–865.
Check BPC-157 against your full medication list
Allmeds AI Pharmacist scans interactions, schedules, and risk flags across your entire medication profile, in minutes.